GSK Secures $1 Billion RNA Licensing Collaboration in China
GSK announced a multi-year licensing collaboration with a Chinese biotech partner for mRNA vaccines and therapeutics in Greater China, unlocking up to $1 billion in development, regulatory and sales milestones. The pact grants rights to GSK's preclinical and clinical RNA candidates and access to China-based R&D and manufacturing capabilities.
1. Deal Terms and Scope
On February 24, 2026, GSK signed a multi-year licensing collaboration with a Chinese biotech partner granting rights to develop and commercialize mRNA vaccines and therapeutics in Greater China, with potential milestone and royalty payments totaling up to $1 billion.
2. Pipeline Expansion
The agreement covers GSK’s preclinical and clinical RNA candidates targeting infectious diseases and oncology, while providing access to local R&D networks and manufacturing sites to accelerate trial initiation and regulatory filings within China.
3. Financial and Strategic Impact
GSK will receive an upfront payment plus staged development, regulatory and sales milestones that could bolster its Asia-Pacific revenue growth and enhance long-term shareholder value by expanding the company’s global mRNA footprint.